Compugen Ltd. · NASDAQ:CGEN

Compugen — CIMT Annual Meeting 2023

16 slides from Compugen's conference presentation, May 5, 2023

  1. Slide 1: Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody

    Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor activity CIMT Annual Meeting Dr. Eran Ophir, SVP Research & Drug Discovery May 5, 2023

  2. Slide 2: Cytokines: powerful tools with challenging therapeutic window

    Cytokines: powerful tools with challenging therapeutic window • Short half life • Short half life • Short half-life • Inhibited by being • Pleiotropy • Systemic inflammation bound to high affinity • Vascular leak syndrome • Myelotoxicity binding protein • Cardiotoxicity • Hepatoxicity • Short half-l

  3. Slide 3: IL-18 stimulates both innate & adaptive immune system

    IL-18 stimulates both innate & adaptive immune system Myeloid/ DAMPs Cancer Inflammasome IL-18 is: cells IFNγ Pro-IL-18 • An effector cytokine • Secreted upon IL-18 Inflammasome MγD88 activation IL-18R NF-ĸB • Upregulated in the TME T/NK cells 3 DAMPs- Damage-associated molecular patterns TME- tumor

  4. Slide 4: IL-18 binding protein is a natural inhibitor of IL-18

    IL-18 binding protein is a natural inhibitor of IL-18 Myeloid/ DAMPs Cancer Inflammasome IL-18 binding cells IFNγ protein (BP): Pro-IL-18 IL-18BP • Binds IL-18 and blocks its immune stimulatory activity IL-18 • IL-18BP secretion is MγD8 IL-18R 8 increased via an IL-18 negative feedback T/NK cells me

  5. Slide 5: COM503, a potential first-in-class anti-IL-18BP blocker antibody that unleashes endogenous IL-18

    COM503, a potential first-in-class anti-IL-18BP blocker antibody that unleashes endogenous IL-18 in the TME Myeloid/ DAMPs Cancer Inflammasome COM503: cells IFNγ Pro-IL-18 Has the potential to IL-18BP COM503 Induce potent anti-tumor responses and IL-18 pronounced TME- IL-18R MγD88 NF-ĸB constrained

  6. Slide 6: Unlike other cytokines, inflammasome induced cytokines such as IL-18 and IL-1b are abundant

    Unlike other cytokines, inflammasome induced cytokines such as IL-18 and IL-1b are abundant in the TME 1000000 NSCLC Esophageal DAMPs H&N Bladder Pancreas Renal Inflammasome Stomach Breast Endometrial Ovary 100000 Cytokine (pg/gr) Colorectal Rectal 10000 IL-18 IL-1b 1000 100 T and NK activation Dual

  7. Slide 7: IL-18 pathway is upregulated in cancer patients and elevated across indications

    IL-18 pathway is upregulated in cancer patients and elevated in the TME across indications IL-18 is upregulated in serum of cancer IL-18Ra is induced on IL-18 is expressed in the TME patients and elevated in the TME TILs in the TME across indications NK CD4 CD8 0.8924 0.0064 0.1633 1000000 ✱✱✱✱ 1024

  8. Slide 8: IL-18BP-Bound IL-18 levels are above the amount required for T cell activation in vitro

    IL-18BP-Bound IL-18 levels in the TME are above the amount required for T cell activation in vitro IL-18 activates TILs at concentrations In most tumors IL-18BP-bound IL-18 level is from ~1ng/ml above ~1ng/ml 240 IL18 bound (ng/gr) 160 500 80 TIL412 IFN [pg/ml] 400 300 +56% 200 +188% 16 12 100 8 0

  9. Slide 9: Compugen identified IL-18BP while querying for TAM negative feedback immunosuppression mechanism

    Compugen identified IL-18BP while querying for TAM negative feedback immunosuppression mechanism Correlation of IL-18BP to IL-18BP is upregulated in myeloid populations IL-18BP is expressed in the TME across PD-L1 in breast and H&N cancer in the TME across indications (scRNA data) indications (ELISA

  10. Slide 10: COM503 is a fully human, high affinity Anti-IL18BP Ab that restores human TIL and NK cell activity

    COM503 is a fully human, high affinity Anti-IL18BP Ab that restores human TIL and NK cell activity Antibody characteristics Releases IL-18 Fully human High affinity Enhances T and from pre-formed IgG4 antibody (<1pM KD) NK cell activation IL-18:IL-18BP complex COM503 restores TILs activity COM503 re

  11. Slide 11: Anti-IL-18BP surrogate Ab demonstrates monotherapy activity across murine syngeneic tumor models

    Anti-IL-18BP surrogate Ab demonstrates monotherapy activity across murine syngeneic tumor models aIL-18BP Ab inhibits tumor growth aIL-18BP Ab inhibits tumor growth in aIL-18BP Ab inhibits tumor growth in in E0771 orthotopic mouse breast B16F10-hmgp100 mouse melanoma MC38ova mouse CRC tumor model tu

  12. Slide 12: Anti-IL-18BP surrogate Ab demonstrates combo activity with anti-PD-L1 and induces immune memory

    Anti-IL-18BP surrogate Ab demonstrates combo activity with anti-PD- L1, modulate the TME & induces immune memory in E0771 aIL-18BP Ab + aPD-L1 Ab inhibit tumor growth in aIL-18BP Ab +%77 E0771 orthotopic mouse breast tumor model monotherapy +258.5% 1000 ✱✱✱✱ # TNFa +IFN + NK/mg tumor # GrB+IFN + C

  13. Slide 13: Anti-IL-18BP Ab modulates tumor microenvironment without affecting the periphery

    Anti-IL-18BP Ab modulates tumor microenvironment without affecting the periphery in murine tumor model Monotherapy with anti-IL-18BP Ab immune-modulated TME in MC38ova model +136% +76% +100% +168% +54% ✱✱ +40 p = 0.0519 MHC-II levels on DC (MFI) ✱✱✱ ✱✱ %✱ # CD8+CD69+CD107+ +85% ✱✱ # DC cells/g tumor

  14. Slide 14: Anti-IL18BP Ab is expected to have a better therapeutic window than recombinant cytokines

    Anti-IL18BP Ab is expected to have a better therapeutic window than recombinant cytokines Administration of anti-mIL-18BP Ab to mice did not affect serum cytokines in contrast to engineered mouse IL-18* IFNg TNFa MCP1 IL6 200 300 400 5000 Isotype control *Engineered IL-18 does not αIL-18BP Ab 150 30

  15. Slide 15: Summary

    Summary ➢ IL-18 is upregulated in the TME and is inhibited by IL-18BP, which is induced in the TME in response to IFN ➢ Blocking IL-18BP in murine cancer models inhibit tumor growth as mono and in combo with anti-PD-L1 antibody ➢ Immune modulation following treatment is restricted to the TME sugges

  16. Slide 16: Thank you!

    Thank you! Acknowledgments: Assaf Menachem, Zoya Alteber, Gady Cojocaru, Tal Fridman Kfir, Dan Blat, Olga Leiderman, Moran Galperin, Lital Sever, Nadav Cohen, Keren Cohen, Liron Soffer, Karin Meyer, Keren Menachem, Hadas Compugen Ltd. Holon, Israel Galon Tilleman, Michal Perpinial, Evgeny Tatirovsky

Compugen — CIMT Annual Meeting 2023 on 6ix